A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Recruiting now · Phase 2

Conditions studied: Advanced Solid Tumors

In brief

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Key facts

Study ID

NCT06895928

Run by

Shanghai Hengrui Pharmaceutical Co., Ltd.

People needed

400

Starts

2025-03-28

Expected to finish

2028-12-01

Last updated by the study team

2025-04-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The age of signing the informed consent is 18 -70 years, regardless of gender.
• At least one measurable lesion according to RECIST v1.1 criteria.
• The ECOG score is 0 or 1.
• Expected survival ≥12 weeks.
• Good level of organ function.
• Have the ability to give informed consent and to comply with the treatment plan.
• Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.

You may not qualify if…

• Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
• Spinal cord compression not cured by surgery and/or radiotherapy.
• Subjects with uncontrolled tumor-related pain.
• Received antitumor therapy within 4 weeks before the start of the study.
• Subjects with severe cardiovascular and cerebrovascular disease.
• History of immunodeficiency, including a positive HIV test.

Where it is running

• Shanxi Cancer hospital — Taiyuan, Shanxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.